Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech
- Strong market penetration with 11 of top 20 medtech companies and 7 of top 10 medtech CROs adopting Veeva's platform
- Customers report significant efficiency gains: 50% faster study build times and 80% reduction in duplicate documents
- Notable customer success stories from major companies like Alcon, LifeNet Health, and Smith+Nephew showing concrete benefits
- Platform ensures regulatory compliance while enabling scalability for growth
- None.
Insights
Veeva's clinical platform gaining significant medtech market share with measurable efficiency improvements for customers, strengthening its industry position.
Veeva Systems has reached a significant milestone with its clinical applications penetrating the medical technology sector. The adoption by more than 50 medtech companies—including 11 of the top 20 medtech firms and 7 of the top 10 medtech CROs—demonstrates Veeva's expanding footprint in this specialized market segment.
The company's success in penetrating the medtech clinical trials space is particularly noteworthy as it represents a strategic expansion beyond Veeva's traditional pharmaceutical customer base. This diversification strengthens Veeva's overall market position and creates additional revenue streams.
Customer testimonials in the release highlight substantial operational improvements: 50% faster study build times with Veeva EDC, 80% reductions in duplicate trial documents with Veeva eTMF, 90% reduction in quality control time at Smith+Nephew, and 50% standardization in one year at Alcon. These metrics demonstrate quantifiable efficiency gains that justify the switch from legacy systems to Veeva's platform.
The release indicates a clear trend of medical device and diagnostic companies moving away from disconnected legacy solutions toward Veeva's connected applications. This shift aligns with the industry's increasing regulatory requirements and need for scalable, compliant solutions across global markets. As medtech clinical trials grow in complexity and volume, Veeva is positioning itself as the infrastructure provider enabling faster product development while maintaining regulatory compliance.
More than 50 medtech companies, including 11 of the top 20, have adopted Veeva clinical applications for greater efficiency and speed
With a growing number of medical device and diagnostic clinical trials executed on Veeva Clinical applications, companies can gain the scalability to grow while maintaining compliance with local, regional, and global regulations. Medtechs of all sizes use Veeva to drive improvements, with customers achieving
"It's exciting to partner with the industry as it moves to Veeva MedTech for a complete and connected medical device and diagnostics clinical trials infrastructure," said Kevin Liang, vice president of clinical strategy at Veeva MedTech. "We're working with leading medtechs to advance study execution, collaboration, and innovation to bring life-changing products to patients faster."
What the medtech clinical industry is saying about Veeva:
"With Veeva EDC, we've partnered closely with their team to enhance the global library and develop reusable standards.," said Leianne Ebert, head of clinical data operations at Alcon. "We focused on getting standards right, and that commitment drove
"Veeva allows us to collect study data consistently in a manner that regulatory agencies will accept," said Kimberly Dorsch, vice president of global clinical affairs at LifeNet Health. "Whether it's a registry study or an IDE/IND study supporting a PMA/BLA, the data's going to be collected the exact same way and in a compliant manner."
"Since implementing Veeva eTMF, we've reduced our quality control time by over
Learn more about Veeva Clinical Platform applications for medtech at veeva.com/MedTechClinical.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/medtech-industry-establishes-foundation-for-clinical-trials-with-veeva-medtech-302477387.html
SOURCE Veeva Systems
FAQ
How many medtech companies have adopted Veeva Systems' (VEEV) clinical applications?
What efficiency improvements are companies seeing with Veeva's (VEEV) clinical platform?
How does Veeva's (VEEV) platform help with regulatory compliance?
What results did Alcon achieve using Veeva's (VEEV) EDC platform?
How has Smith+Nephew benefited from implementing Veeva (VEEV) eTMF?
